Urgent health challenges for the next decade: WHO
Stopping Infectious diseases
Urgent health challenges for the next decade: WHO
Protecting the medicines that protect us
Urgent health challenges for the next decade: WHO
Earning public trust
FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies?
Editorial article
Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health
Editorial article

 

FDA-approves the first therapy in 2018 for the Seizures associated with Dravet syndrome

Dravet syndrome is a rare genetic condition that appears during the first year of life with frequent fever-related seizures (febrile seizures). Later, other types of seizures typically arise, including myoclonic seizures (involuntary muscle spasms). The U.S. Food and Drug Administration in June 2018 approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from Cannabis sativa. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. Previously there had been no FDA-approved therapy for use in Dravet syndrome. FDA Officials also approved stiripentol (Diacomit) for the treatment of seizures associated with Dravet syndrome.

WELCOME TO NEUROPHARMAC JOURNAL

Aim and Scope of the Journal

NeuroPharmac Journal is an open-access official peer-reviewed International Journal Publishing three Issues per year and allowing open access to abstracts and full-text. The term “Neuro” is devoted to the promotion of Medical and related disciplines like Clinical research, Nursing research, Physiotherapy research, Occupational therapy research, Pharmaceutical research, Pharmacognosy & Phytochemistry, Pharmacology and Phytopharmacology, Pharmacy Practice, Clinical & Hospital Pharmacy with focus on various neurology updates on neurological disorders and their management. 

While the term “Pharmac” is related to research, review and current updates in Pharmaceutical Science field including Pharmaceutics, Pharmacology, Pharmaceutical, and Medicinal Chemistry, Pharmacognosy and Phytochemistry, Clinical and Hospital Pharmacy and Pharmaceutical Analysis.

The Journal invites reviews, full-length original research articles, concise reports, case study, short-rapid communications of clinical and experimental nature including modern, traditional and epidemiological studies that contribute significantly to the existing knowledge base or open up new frontiers of knowledge in the field of Neurology (medical) and Pharmaceutical Science.

Review articles based primarily on the author’s own research on internationally important topics will be accepted. Short communications to the editor are also welcome. The primary criteria for acceptance and publication are scientific thoroughness and the potential to advance the field of Medical and Pharmaceutical science.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License. (digital archiving policy= LOCKSS)

 

Announcements
  • News
    Welcome to NeuroPharmac Journal

    Articles are Invited for Volume 5, Issue 1 (January-April 2020)